AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Boundless Bio: HC Wainwright Maintains Buy Rating, Lowers PT to $4
ByAinvest
Monday, Aug 11, 2025 6:47 am ET1min read
Boundless Bio: HC Wainwright Maintains Buy Rating, Lowers PT to $4
In a recent update, HC Wainwright & Co. has maintained its buy rating for Boundless Bio (NASDAQ: BOLD) but has lowered its price target to $4.00. This decision comes on the heels of the biotechnology company's second-quarter 2025 results, which were released on August 5, 2025. The update reflects a cautious view of the company's near-term prospects and the potential challenges it may face in its clinical trials and regulatory submissions.Boundless Bio reported a significant reduction in research and development expenses for the second quarter of 2025, down to $12.2 million from $14.7 million in the same period of 2024 [1]. This decrease, along with a reduction in general and administrative expenses, contributed to a net loss of $15.7 million (GAAP) for the quarter, compared to $17.0 million (GAAP) in the same period of 2024. The company ended the quarter with $127.1 million in cash, cash equivalents, and short-term investments, which management expects to fund operations into the first half of 2028.
The analyst's decision to lower the price target reflects a more conservative outlook on the company's ability to meet its clinical milestones and generate revenue. While the company has made progress in its pipeline programs, including the nomination of BBI-940 as a development candidate and the expansion of the POTENTIATE trial for its BBI-355 program, the success of these programs remains uncertain. The company will need to generate compelling proof-of-concept results and navigate the regulatory submission process for BBI-940 to maintain investor confidence.
Investors should continue to monitor Boundless Bio's clinical trials and regulatory submissions, as well as the company's cash position, to assess its near-term prospects. The company's ability to generate revenue and achieve profitability will depend on its success in these areas.
References:
[1] https://www.nasdaq.com/articles/boundless-bio-bold-q2-rd-drops-17
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet